DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,463,153 B2 Morariu (45) Date of Patent: Oct

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,463,153 B2 Morariu (45) Date of Patent: Oct USOO9463153B2 (12) United States Patent (10) Patent No.: US 9,463,153 B2 Morariu (45) Date of Patent: Oct. 11, 2016 (54) TOPICAL MACQUI BERRY FORMULATION A61K 8/44 (2013.01); A61K 8/46 (2013.01); A61K 8/4913 (2013.01); A61K 8/602 (71) Applicant: Tracie Martyn INTERNATIONAL, (2013.01); A61K 36/185 (2013.01); A61O I/00 LLC, Brooklyn, NY (US) (2013.01); A61O 19/00 (2013.01); A61O 19/08 (2013.01); A61 K 2800/26 (2013.01); (72) Inventor: Marius Morariu, Brooklyn, NY (US) A61 K 2800/52 (2013.01); A6 IK 2800/522 (2013.01) (73) Assignee: tadt,Marge International LLC, (58) Field of Classification Search (*) Notice: Subject to any disclaimer, the term of this See application file for complete search history. patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. (56) References Cited (21) Appl. No.: 14/480,182 U.S. PATENT DOCUMENTS (22) Filed: Sep. 8, 2014 2002/0187114 A1*ck 12/2002 Mankovitz. ............. A61ks: 2005/00 13880 A1* 1/2005 Magnuson et al. ........... 424,732 (65) Prior Publication Data US 2014/0377338A1 Dec. 25, 2014 OTHER PUBLICATIONS Related U.S. Application Data Miranda-Rottmann et al. Juice and phenolic fractions of the berry Aristotelia chilensis inhibit LDL oxidation in vitro and protect (63) Continuation of application No. 13/226,834, filed on human endothelial cells against oxidative stress. Journal of agricul Sep. 7, 2011, now Pat. No. 8,828,458, which is a tural and food chemistry, 50 (26): 7542-7, 2002.* continuation of application No. 1 1/525,288, filed on Sep. 21, 2006, now abandoned. * cited by examiner (60) Provisional application No. 60/719,530, filed on Sep. 21, 2005. Primary Examiner — Qiuwen Mi (74) Attorney, Agent, or Firm — Bryan D. Zerhusen; (51) Int. Cl. Locke Lord LLP A6 IK 36/00 (2006.01) A 6LX 8/97 (2006.01) (57) ABSTRACT A6 IK 8/44 (2006.01) A6 IK 8/46 (2006.01) The present invention provides a topical formulation and A6 IK 8/49 (2006.01) method of use where the formulation comprises macqui A6 IK 8/60 (2006.01) berry or a macqui berry extract containing anthocyanins A6 IK 36/185 (2006.01) having a very high oxygen radical absorbance capacity A61O 19/08 (2006.01) (ORAC). The formulation provides the macqui berry in a A6 IK 8/14 (2006.01) stabilized form which includes a glucuronide or gly A61O I/00 (2006.01) curonide, a photostabilizing agent, encapsulation, or light A61O 19/00 (2006.01) and/or air-blocking packaging. (52) U.S. Cl. CPC. A61K 8/97 (2013.01); A61K 8/14 (2013.01); 3 Claims, No Drawings US 9,463,153 B2 1. 2 TOPICAL MACQUI BERRY FORMULATION the prevention and reduction of wrinkles, increase in skin elasticity, etc., which are caused by a reduction in skin CROSS-REFERENCE TO RELATED collagen. APPLICATIONS For ripe berries, a rich source of anthocyanin antioxidants, there is generally a linear relationship between ORAC values and anthocyanin content. High ORAC ratings are This application is a Continuation application of U.S. generally defined as greater than 25umole of Trolox equiva patent application Ser. No. 13/226,834, filed Oct. 7, 2011, lents (TE)/g. In most fruits, ORAC values ranged from 7.8 now Issued Patent No. 8,828,458, issue date: Sep. 9, 2014: to 33.7 umole TE/g of fresh berries and the ORAC values of which is a Continuation application of U.S. patent applica the leaves range from 69.7 to 182.2 mole TE/g (Wang SY. tion Ser. No. 11/525,288, filed Sep. 21, 2006, abandoned; 10 Lin H S., J Agric Food Chem. 2000 February; 48(2):140-6). which claims priority to Provisional Patent Application No. Comparatively, a fruit with an ORAC value of 8 umol TE/g 60/719.530, filed Sep. 21, 2005, the entire contents of the of fresh berries will have an ORAC value of about 35umol aforementioned applications are hereby incorporated herein TE/g of driedberries and an ORAC of 34 umol TE/g of fresh by reference. berries corresponds with an ORAC of 162 umol TE/g dried 15 matter. Black raspberries have a very high ORAC of 77 FIELD OF THE INVENTION umoleTE/g while boysenberries have an ORAC of 48 umole TE/g, and red raspberries and blueberries have an ORAC of The present invention relates to the topical application of 24 and 23 umole TE/g, respectively. (http://www.decker compositions containing macqui berry or macqui berry farm.com/antioxidants.html). Acai is another fruit having a extract in a topical formulation for the prevention and/or high ORAC content (167 ORAC units/g according to Bruns treatment of damage to skin, particularly skin damage result wick Laboratories). Other fruit having high ORAC values ing from chronoaging and photoaging. include pomegranate (33.1 ulumole TE/g) and aronia berry (62 Lumole TE/g) as well as whole coffee fruit extract (6250 BACKGROUND OF THE INVENTION ORAC units per gram according to Brunswick Laborato 25 ries). The stage at which the plant is harvested affects the ORAC value. Blackberries have their highest ORAC values Skin is Subject to abuse by many extrinsic (environmen during the green stages, whereas red raspberries have their tal) factors as well as intrinsic factors. A common extrinsic highest ORAC values when ripe. The ORAC may be factor is exposure to ultraviolet radiation. Whether extrinsic obtained by using the method described by the U.S. Depart or intrinsic, the abuse results in skin aging. Skin aging ment of Agriculture's Agricultural Research Service (Prior happens in two ways: (1) through the natural aging process 30 and Cao, 83(4) J. AOAC INT. 950-6 (2000)). Additionally, which dermatologists call chronological aging (also known testing for ORAC, H-ORAC, N-ORAC, S-ORAC, and as chronoaging); and (2) through UV rays in sunlight ORAC-E (high throughput ORAC for oil-in-water emul accelerating the aging process which dermatologists call sion) is available from Brunswick Laboratories (www photoaging. Chronoaging results in thinning, loss of elas .brunswicklabs.com). ticity and general degradation of skin. As the skin naturally 35 Anthocyanins have been formulated in topical form. For ages, there is a reduction in the cells and blood vessels that example, U.S. Pat. Pub. 2004/0022818 provides a skin care Supply the skin. There is also a flattening of the dermal composition comprising fruit particles. Red and blue fruits, epidermal junction which results in weaker mechanical as well as other fruits which contain anthocyanins are resistance. As a consequence, older persons are more Sus included in this composition. Similarly, U.S. Pub. 2003/ ceptive to blister formation in cases of mechanical traumas 40 0161897 and U.S. Pat. No. 6,361,786 provide a topical or disease processes (Oikarinen et al., Photodermatal. Pho antimicrobial factor having fruit juice (cranberry, Aronia toimmunol. Photomed., 7:3-4 (1990)). berry, blackberry, grape or blueberry) and polyvinylprolidi By contrast, photoaging, or premature aging, is a process none. A topical oil-in-water emulsion containing a surfac in which the skin changes in appearance as a result of tant/emulsifier and a lipid, which may be an anthocyanin repeated exposure to Sunlight. Typically, photoaging occurs 45 containing berry extract, is provided by WO98/05294. U.S. in areas of habitual exposure, Such as the scalp, face, ears, Pat. No. 5,011,855 provides a cosmetic composition having neck, chest, forearms and hands. The changes associated a-linolenic acid and an oil extracted from Ribes genus fruits. with photoaging include elastosis, atrophy, wrinkling, vas However, there are problems associated with these and cular changes (diffuse erythema, ecchymoses, and telangi other uses of antioxidants in a topical formulation. Particu ectasias), pigmentary changes (lentigines, freckles, and 50 larly, antioxidants are readily oxidized and lose their anti areas of hypo- and hyper-pigmentation), and the develop oxidant capacity. Additionally, some of the oxidation prod ment of seborrheic keratosis, actinic keratosis, comedones ucts of antioxidants will have a deleterious effect; for and cysts. example, vitamin C oxidizes to dehydroascorbate which is Antioxidants are useful agents treating the skin from known to lead to the formation of advanced glycation damage caused by chronoaging and photoaging. The most 55 endproducts (AGEs) and therefore increase the signs of useful antioxidants are those that provide the highest capac aging skin. ity to absorb free radicals. The oxygen radical absorbance Therefore, a topical formulation containing an antioxidant capacity (ORAC) is a measurement of this (Dreher F. with a much higher ORAC and consequently greater anti Maibach H. Curr Probl Dermatol. 2001:29:157-64.) Antho oxidant power is needed in combination with a formulation cyanins are a type of antioxidants that generally encompass 60 that protects the antioxidant from degradation and loss of the a class of flavonoid compounds that are naturally occurring, anti-oxidative power to be used in treating and protecting the water-soluble compounds, responsible for the red, purple, skin. and blue colors of many fruits, vegetables, cereal grains, and flowers. Most anthocyanins have a high ORAC rating com SUMMARY OF THE INVENTION pared to other antioxidants and make them particularly 65 useful for their topical antioxidative properties. Addition It is an object of the present invention to provide a ally, anthocyanins are collagenase inhibitors, which helps in composition and method for treating and protecting the skin. US 9,463,153 B2 3 In accordance therewith, a method and composition is TABLE 1-continued provided for treating skin, comprising a topical composition containing macqui berry in a stabilized form and the admin ORAC value istration of an effective amount of the topical composition to Fruit (Imole TEg) the skin.
Load more

Recommended publications
  • Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
    Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av.
    [Show full text]
  • The Benefits of Flavonoids in Diabetic Retinopathy
    nutrients Review The Benefits of Flavonoids in Diabetic Retinopathy 1, 1, 2,3,4,5 1,2,3,4, Ana L. Matos y, Diogo F. Bruno y, António F. Ambrósio and Paulo F. Santos * 1 Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal; [email protected] (A.L.M.); [email protected] (D.F.B.) 2 Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal; [email protected] 3 Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal 4 Clinical Academic Center of Coimbra (CACC), 3004-561 Coimbra, Portugal 5 Association for Innovation and Biomedical Research on Light and Image (AIBILI), 3000-548 Coimbra, Portugal * Correspondence: [email protected]; Tel.: +351-239-240-762 These authors contributed equally to the work. y Received: 10 September 2020; Accepted: 13 October 2020; Published: 16 October 2020 Abstract: Diabetic retinopathy (DR), one of the most common complications of diabetes, is the leading cause of legal blindness among adults of working age in developed countries. After 20 years of diabetes, almost all patients suffering from type I diabetes mellitus and about 60% of type II diabetics have DR. Several studies have tried to identify drugs and therapies to treat DR though little attention has been given to flavonoids, one type of polyphenols, which can be found in high levels mainly in fruits and vegetables, but also in other foods such as grains, cocoa, green tea or even in red wine.
    [Show full text]
  • Chondroprotective Agents
    Europaisches Patentamt J European Patent Office © Publication number: 0 633 022 A2 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 94109872.5 © Int. CI.6: A61K 31/365, A61 K 31/70 @ Date of filing: 27.06.94 © Priority: 09.07.93 JP 194182/93 Saitama 350-02 (JP) Inventor: Niimura, Koichi @ Date of publication of application: Rune Warabi 1-718, 11.01.95 Bulletin 95/02 1-17-30, Chuo Warabi-shi, 0 Designated Contracting States: Saitama 335 (JP) CH DE FR GB IT LI SE Inventor: Umekawa, Kiyonori 5-4-309, Mihama © Applicant: KUREHA CHEMICAL INDUSTRY CO., Urayasu-shi, LTD. Chiba 279 (JP) 9-11, Horidome-cho, 1-chome Nihonbashi Chuo-ku © Representative: Minderop, Ralph H. Dr. rer.nat. Tokyo 103 (JP) et al Cohausz & Florack @ Inventor: Watanabe, Koju Patentanwalte 2-5-7, Tsurumai Bergiusstrasse 2 b Sakado-shi, D-30655 Hannover (DE) © Chondroprotective agents. © A chondroprotective agent comprising a flavonoid compound of the general formula (I): (I) CM < CM CM wherein R1 to R9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The 00 00 above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to (Q protect cartilage, and thus, is extremely effective for the treatment of arthropathy. Rank Xerox (UK) Business Services (3. 10/3.09/3.3.4) EP 0 633 022 A2 BACKGROUND OF THE INVENTION 1 . Field of the Invention 5 The present invention relates to an agent for protecting cartilage, i.e., a chondroprotective agent, more particularly, a chondroprotective agent containing a flavonoid compound or a stereoisomer thereof, or a naturally occurring glycoside thereof.
    [Show full text]
  • 16441-16455 Page 16441 S
    S. Umamaheswari*et al. /International Journal of Pharmacy & Technology ISSN: 0975-766X CODEN: IJPTFI Available Online through Research Article www.ijptonline.com EFFECT OF FLAVONOIDS DIOSMIN, MORIN AND CHRYSIN ON CHANG LIVER CELL LINE K.S. Sridevi Sangeetha1, S. Umamaheswari1*, C. Uma Maheswara Reddy1, S. Narayana kalkura2 1 Department of Pharmacology, Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai 2Crystal Growth Centre, Anna University, Guindy, Chennai. Email: [email protected] Received on 06-08-2016 Accepted on 27-08-2016 Abstract Objective: To evaluate the effect of selected flavonoids diosmin, morin and chrysin on chang cell (normal human liver cells) line by using cell viability assay. Methods: The cell viability assay on chang cell was determined using MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5- diphenyltetrazolium bromide) assay. Diosmin, morin and chrysin were subjected in the concentration of 1.625 µM, 3.125 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, 100 µM and 500 µM respectively. Results: The cytoprotective activity by MTT method showed that the IC 50 value of diosmin, morin and chrysin was 101.91 µM, 14.62 µM and 70.00 µM respectively. Conclusion: Out of the three flavonoids, diosmin and chrysin were proven to have very good cytoprotective activity against Chang cell line. The order of activity was found to be Disomin > Chrysin > Morin. Key words: Flavonoid, Chang cell line, Diosmin, Morin, Chrysin Introduction Plant produces different types of secondary metabolites and one such group is flavonoid. They are polyphenolic in nature and present in different part of the plant like leaves, flowers, fruits, vegetable etc.
    [Show full text]
  • Electrochemical Behaviour of Flavonoids on a Surface
    44 Biomed. Papers 149 (Supplement 1), 2005 ELECTROCHEMICAL BEHAVIOUR 3/ OF FLAVONOIDS ON A SURFACE / / OF A CARBON PASTE ELECTRODE 2 4 8 / Pavel Hanuštiaka, Radka Mikelováa, O 1 5/ a, b c c 7 David Potěšil , Petr Hodek , Marie Stiborová , 1 2 René Kizeka 6/ 6 a Department of Chemistry and Biochemistry, Faculty 3 of Agronomy, Mendel University of Agriculture and 4 5 Forestry, Zemědělská 1, CZ-613 00 Brno, Czech Republic O b Department of Analytical Chemistry, Faculty of Science, Fig. 1. Flavonoid structure made of two benzene rings Masaryk University, Kotlářská 37, CZ-611 37 Brno, linked by heterocyclic pyran. Czech Republic c Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128 40 Prague, of health and could significantly support a physiological Czech Republic capacity or decrease a possibility of a disease appearing3. e-mail: [email protected] Different groups of metabolites such as phenolic acids, lignans, phytosterols, carotenoids, glucosinolates and Key words: Flavonoids/Antioxidant/Rutin/Quercetin/ also flavonoids influence human health as described Quercitrin/Diosmin/Chrysin/Carbon paste electrode/ above2. Flavonoids comprise a wide-ranging group of Square wave voltammetry plant phenols. Up to now, more than 4,000 of flavonoid compounds are known and new ones have been still dis- covering. Flavonoids are derived from heterocyclic oxy- ABSTRACT gen compound, flavan, which is formed by two benzene rings linked by heterocyclic pyran (Fig. 1). All three rings Recent papers discuss relation of flavonoid compounds could be substituted by hydroxy- or methoxy-groups and and tumour diseases. In addition it is impossible to say particular derivates differs only in degree of substitution that effect of flavonoids is positive or negative without and oxidation.
    [Show full text]
  • Drug Bioavailability Enhancing Agents of Natural Origin (Bioenhancers) That Modulate Drug Membrane Permeation and Pre-Systemic Metabolism
    pharmaceutics Review Drug Bioavailability Enhancing Agents of Natural Origin (Bioenhancers) that Modulate Drug Membrane Permeation and Pre-Systemic Metabolism Bianca Peterson, Morné Weyers , Jan H. Steenekamp, Johan D. Steyn, Chrisna Gouws and Josias H. Hamman * Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), North-West University, Potchefstroom 2520, South Africa; [email protected] (B.P.); [email protected] (M.W.); [email protected] (J.H.S.); [email protected] (J.D.S.); [email protected] (C.G.) * Correspondence: [email protected]; Tel.: +27-18-299-4035 Received: 11 December 2018; Accepted: 24 December 2018; Published: 16 January 2019 Abstract: Many new chemical entities are discovered with high therapeutic potential, however, many of these compounds exhibit unfavorable pharmacokinetic properties due to poor solubility and/or poor membrane permeation characteristics. The latter is mainly due to the lipid-like barrier imposed by epithelial mucosal layers, which have to be crossed by drug molecules in order to exert a therapeutic effect. Another barrier is the pre-systemic metabolic degradation of drug molecules, mainly by cytochrome P450 enzymes located in the intestinal enterocytes and liver hepatocytes. Although the nasal, buccal and pulmonary routes of administration avoid the first-pass effect, they are still dependent on absorption of drug molecules across the mucosal surfaces to achieve systemic drug delivery. Bioenhancers (drug absorption enhancers of natural origin) have been identified that can increase the quantity of unchanged drug that appears in the systemic blood circulation by means of modulating membrane permeation and/or pre-systemic metabolism.
    [Show full text]
  • Comparative Study on Melanin Production and Collagen Expression Profile of Polyphenols and Their Glycosides
    Indian Journal of Biochemistry & Biophysics Vol. 56, April 2019, pp. 137-143 Comparative study on melanin production and collagen expression profile of polyphenols and their glycosides Puspalata Bashyal1, Ϯ, Ha Young Jung1, Ϯ, Ramesh Prasad Pandey1, 2* & Jae Kyung Sohng1, 2* 1Department of Life Science and Biochemical Engineering; 2Department of Pharmaceutical Engineering & Biotechnology, Sun Moon University, 70 Sunmoon-ro 221, Tangjeong-myeon, Asan-si, Chungnam -31460, Republic of Korea Received 29 May 2018; revised 29 November 2018 A total of twenty different polyphenol aglycones and their biochemically synthesized glycoside derivatives were accessed for cell toxicity, collagen synthesis and melanin content inhibition assays to illustrate the double-edged sword role of glycobiology, in particular, modification of hydroxyl group in polyphenol structure without glycone moiety over anti-aging and defense to oxidative stress in skin dermatology. All molecules at (0.1-200) µM concentration inhibited cell growth in a dose dependent manner on human dermal fibroblast (HDF) and melanoma skin cancer (B16F10) cells. At lower concentrations of (0.1-10) µM, most of the molecules were nontoxic to HDF cells, while the same molecules were toxic to B16F10 cells except astilbin (6), baicalein (13), baicalein 7-O-β-D-glucoside (14) and mangostin (18). Results showed that two molecules, quercetin (1) and diosmin (17), inhibited melanogenesis in α-melanocyte stimulating hormone (α-MSH)-stimulated melanoma skin cancer cells (B16F10) in comparison to the control at 0.1 µM concentration, indicating the possible use of these molecules in skin-whitening products. Similarly, the maintenance of collagen in HDF cells was found to be highly activated by the compound, kaempferol (11), at 1.0 µM concentration, at which the cell viability was above 95%.
    [Show full text]
  • Understanding Chronic Venous Disease: a Critical Overview of Its Pathophysiology and Medical Management
    Journal of Clinical Medicine Review Understanding Chronic Venous Disease: A Critical Overview of Its Pathophysiology and Medical Management Miguel A. Ortega 1,2,3,† , Oscar Fraile-Martínez 1,2,† , Cielo García-Montero 1,2,† , Miguel A. Álvarez-Mon 1,2,*, Chen Chaowen 1, Fernando Ruiz-Grande 4,5, Leonel Pekarek 1,2 , Jorge Monserrat 1,2 , Angel Asúnsolo 2,4,6 , Natalio García-Honduvilla 1,2,‡ , Melchor Álvarez-Mon 1,2,7,‡ and Julia Bujan 1,2,‡ 1 Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain; [email protected] (M.A.O.); [email protected] (O.F.-M.); [email protected] (C.G.-M.); [email protected] (C.C.); [email protected] (L.P.); [email protected] (J.M.); [email protected] (N.G.-H.); [email protected] (M.Á.-M.); [email protected] (J.B.) 2 Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain; [email protected] 3 Cancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain 4 Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain; [email protected] 5 Department of Vascular Surgery, Príncipe de Asturias Hospital, 28801 Alcalá de Henares, Spain 6 Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY 10027, USA 7 Citation: Ortega, M.A.; Immune System Diseases—Rheumatology and Internal Medicine Service, University Hospital Príncipe de Fraile-Martínez, O.; García-Montero, Asturias, (CIBEREHD), 28806 Alcalá de Henares, Spain * Correspondence: [email protected] C.; Álvarez-Mon, M.A.; Chaowen, C.; † These authors contributed equality in this work.
    [Show full text]
  • Inhibition of Xanthine Oxidase-Catalyzed Xanthine and 6-Mercaptopurine Oxidation by Flavonoid Aglycones and Some of Their Conjugates
    International Journal of Molecular Sciences Article Inhibition of Xanthine Oxidase-Catalyzed Xanthine and 6-Mercaptopurine Oxidation by Flavonoid Aglycones and Some of Their Conjugates Violetta Mohos 1,2 , Eszter Fliszár-Nyúl 1,2 and Miklós Poór 1,2,* 1 Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti út 12, H-7624 Pécs, Hungary; [email protected] (V.M.); [email protected] (E.F.-N.) 2 János Szentágothai Research Centre, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary * Correspondence: [email protected]; Tel.: +36-72-536-000 (ext. 35052) Received: 23 March 2020; Accepted: 4 May 2020; Published: 5 May 2020 Abstract: Flavonoids are natural phenolic compounds, which are the active ingredients in several dietary supplements. It is well-known that some flavonoid aglycones are potent inhibitors of the xanthine oxidase (XO)-catalyzed uric acid formation in vitro. However, the effects of conjugated flavonoid metabolites are poorly characterized. Furthermore, the inhibition of XO-catalyzed 6-mercaptopurine oxidation is an important reaction in the pharmacokinetics of this antitumor drug. The inhibitory effects of some compounds on xanthine vs. 6-mercaptopurine oxidation showed large differences. Nevertheless, we have only limited information regarding the impact of flavonoids on 6-mercaptopurine oxidation. In this study, we examined the interactions of flavonoid aglycones and some of their conjugates with XO-catalyzed xanthine and 6-mercaptopurine oxidation in vitro. Diosmetin was the strongest inhibitor of uric acid formation, while apigenin showed the highest effect on 6-thiouric acid production. Kaempferol, fisetin, geraldol, luteolin, diosmetin, and chrysoeriol proved to be similarly strong inhibitors of xanthine and 6-mercaptopurine oxidation.
    [Show full text]
  • Clinical Practice Guidelines for the Management of Hemorrhoids Bradley R
    CLINICAL PRACTICE GUIDELINES The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids Bradley R. Davis, M.D. • Steven A. Lee-Kong, M.D. • John Migaly, M.D. Daniel L. Feingold, M.D. • Scott R. Steele, M.D. Prepared by the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons he American Society of Colon and Rectal Surgeons ing the propriety of any specific procedure must be made (ASCRS) is dedicated to assuring high-quality pa- by the physician in light of all of the circumstances pre- Ttient care by advancing the science, prevention, sented by the individual patient. and management of disorders and diseases of the colon, rectum, and anus. The Clinical Practice Guidelines Com- mittee is composed of Society members who are chosen STATEMENT OF THE PROBLEM because they have demonstrated expertise in the specialty Symptoms related to hemorrhoids are very common in of colon and rectal surgery. This committee was created to the Western hemisphere and other industrialized societies. lead international efforts in defining quality care for condi- Although published estimates of prevalence are varied,1,2 tions related to the colon, rectum, and anus. This is accom- it represents one of the most common medical and surgi- panied by developing Clinical Practice Guidelines based on cal disease processes encountered in the United States, re- the best available evidence. These guidelines are inclusive sulting in >2.2-million outpatient evaluations per year.3 A and not prescriptive. Their purpose is to provide informa- large number of diverse symptoms may be, correctly or in- tion on which decisions can be made rather than to dictate correctly, attributed to hemorrhoids by both patients and a specific form of treatment.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Version 3.0, 04/2013 SUMMARY of PRODUCT CHARACTERISTICS
    Version 3.0, 04/2013 SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT [PRODUCT NAME] 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg diosmin. Excipients with known effect: Each tablet contains 4.626 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Pink (salmon) coloured, oblong, biconvex coated tablets with the inscription D500 on one side. The dimensions of diosmin tablets are 19.1 mm x 7.4 mm x 5.8 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications [PRODUCT NAME] is indicated in adults as a short-term treatment of symptoms of established chronic venous insufficiency (CVI) adjuvant to conventional treatment of CVI. 4.2 Posology and method of administration Posology Adults (≥ 18 years) The recommended daily dose is two tablets: one tablet at noon and one tablet in the evening, with food. The maximum duration of treatment is 2 to 3 months. Paediatric population No data are available. Method of administration For oral use. The tablets should be taken with food. 4.3 Contraindications Hypersensitivity to the active substance, other flavonoids or to any of the excipients listed in section 6.1. 3 4.4 Special warnings and precautions for use This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. The efficacy and safety of the preparation have not been studied in the following groups/conditions, which has to be taken into account when the preparation is used: - children and adolescents (under 18 years).
    [Show full text]